As we age, our bodies go through various changes, including the accumulation of senescent cells that can contribute to chronic inflammation and tissue dysfunction. These dysfunctional cells, also known as “zombie cells,” can have a negative impact on our overall health and well-being. However, recent research from Mayo Clinic suggests that senolytic drugs may hold promise in selectively targeting and eliminating these senescent cells, particularly in otherwise healthy older women.
In a groundbreaking phase 2 randomized controlled trial, researchers at Mayo Clinic administered a senolytic combination of dasatinib and quercetin to 60 healthy women past menopause. Dasatinib is an FDA-approved drug, while quercetin is a natural compound found in some foods. This trial, the first of its kind in healthy aging women, focused on bone metabolism as a marker for the efficacy of the senolytic treatment.
The results of the study, published in Nature Medicine, were promising. The senolytic combination, known as D+Q, showed beneficial effects on bone formation in the participants. However, it was noted that the benefits were more pronounced in individuals with a high number of senescent cells. This group experienced significant increases in bone formation, decreases in bone resorption, and improvements in bone mineral density at the wrist.
Dr. Sundeep Khosla, senior author of the study and an endocrinologist at Mayo Clinic, emphasized the importance of identifying individuals who may benefit from senolytic treatments. He cautioned against the use of commercial products like quercetin without knowing the specific dosing regimen needed for effectiveness and safety.
Furthermore, Dr. Khosla highlighted the potential applications of senolytic drugs beyond aging-related issues. These drugs could be beneficial in addressing various diseases, including idiopathic pulmonary fibrosis, dementia, diabetes, and heart disease. However, the development of more specific and potent senolytic drugs tailored to individual needs is essential for their widespread efficacy.
It is worth noting that individuals with “accelerated aging,” such as cancer survivors post-chemotherapy, may have a higher number of senescent cells and thus stand to benefit from senolytic treatments. Research in this area is ongoing, with the aim of refining the use of senolytic drugs for maximum impact.
Looking ahead, Dr. Khosla and his team underscore the importance of personalized medicine in the realm of senolytic treatments. Customizing these drugs according to potency and the specific senescent cell profiles of individuals could lead to more targeted and effective therapies for a range of age-related and disease-related conditions.
In conclusion, senolytic drugs show promise as a potential intervention for healthy aging women, particularly those with a high burden of senescent cells. As research in this field continues to evolve, the development of tailored senolytic therapies could pave the way for improved health outcomes in aging populations.
Sources:
